DE69840625D1 - Verfahren und zusammensetzungen zur prävention undichen reaktion einschliesslich der sepsis - Google Patents

Verfahren und zusammensetzungen zur prävention undichen reaktion einschliesslich der sepsis

Info

Publication number
DE69840625D1
DE69840625D1 DE69840625T DE69840625T DE69840625D1 DE 69840625 D1 DE69840625 D1 DE 69840625D1 DE 69840625 T DE69840625 T DE 69840625T DE 69840625 T DE69840625 T DE 69840625T DE 69840625 D1 DE69840625 D1 DE 69840625D1
Authority
DE
Germany
Prior art keywords
compositions
processes
reaction including
including sepsis
subjective reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840625T
Other languages
English (en)
Inventor
Kenneth L Becker
Jon C White
Eric S Nylen
Richard H Snider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ENDOCRINOLOGY ASSOCIATES EPC L
Original Assignee
ENDOCRINOLOGY ASSOCIATES EPC L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ENDOCRINOLOGY ASSOCIATES EPC L filed Critical ENDOCRINOLOGY ASSOCIATES EPC L
Application granted granted Critical
Publication of DE69840625D1 publication Critical patent/DE69840625D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
DE69840625T 1997-02-03 1998-01-29 Verfahren und zusammensetzungen zur prävention undichen reaktion einschliesslich der sepsis Expired - Lifetime DE69840625D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/794,740 US5993811A (en) 1997-02-03 1997-02-03 Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
PCT/US1998/000985 WO1998033524A1 (en) 1997-02-03 1998-01-29 Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis

Publications (1)

Publication Number Publication Date
DE69840625D1 true DE69840625D1 (de) 2009-04-16

Family

ID=25163534

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840625T Expired - Lifetime DE69840625D1 (de) 1997-02-03 1998-01-29 Verfahren und zusammensetzungen zur prävention undichen reaktion einschliesslich der sepsis

Country Status (8)

Country Link
US (1) US5993811A (de)
EP (1) EP0988054B1 (de)
JP (1) JP2001527529A (de)
AT (1) ATE424218T1 (de)
AU (1) AU739645B2 (de)
CA (1) CA2279517C (de)
DE (1) DE69840625D1 (de)
WO (1) WO1998033524A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19847690A1 (de) * 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
EP1110970B1 (de) * 1999-12-22 2008-05-14 Dade Behring Marburg GmbH Gegen Procalcitonin gerichtete Antikörper, ihre Herstellung und Verwendung
ATE356874T1 (de) * 1999-12-22 2007-04-15 Dade Behring Marburg Gmbh Lösungen von humanem procalcitonin
WO2001075179A2 (en) * 2000-03-31 2001-10-11 Ludwig Institute For Cancer Research Preprocalcitonin as tumor rejection antigen precursor and uses thereof
WO2003043570A2 (en) 2001-11-15 2003-05-30 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
EP1495756A4 (de) * 2002-04-08 2009-10-28 Takeda Pharmaceutical Therapeutikum zur prävention schwerer sepsis
WO2004005539A1 (en) * 2002-07-05 2004-01-15 The University Of British Columbia Diagnosis of sepsis using mitochondrial nucleic acid assays
DE102007009751A1 (de) * 2007-02-28 2008-09-04 B.R.A.H.M.S Aktiengesellschaft Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens
ES2401703T3 (es) * 2007-08-03 2013-04-23 B.R.A.H.M.S Gmbh Utilización de la procalcitonina (PCT) en la estratificación de riesgo y el pronóstico de los pacientes con una enfermedad primaria no infecciosa
CN102301362B (zh) * 2009-01-15 2014-06-18 艾尔蒙德纳特公司 请求离线配置文件数据用于以隐私敏感方式的在线使用
EP2470910B1 (de) * 2009-08-28 2017-01-11 B.R.A.H.M.S GmbH Procalcitonin zur Prognose von Nebenwirkungen
EP2320237B1 (de) * 2009-10-13 2016-08-03 B.R.A.H.M.S GmbH Procalcitonin zur Diagnose von bakteriellen Infektionen und Führung der Antibiotikabehandlung bei Menschen mit akutem Schlaganfall oder transienten ischämischen Anfällen
EP2657707A1 (de) * 2012-04-26 2013-10-30 B.R.A.H.M.S GmbH Biomarkers zur Diagnose, Vorhersage, Beurteilung und Therapiesynkopenschichtung
HUE057168T2 (hu) 2013-03-15 2022-04-28 Protagonist Therapeutics Inc A hepcidin analógjai és ezek alkalmazása
US10126305B2 (en) * 2013-06-25 2018-11-13 University of Pittsburg—Of the Commonwealth System of Higher Education Proteomic biomarkers of sepsis in elderly patients
NZ726337A (en) 2014-05-16 2023-10-27 Protagonist Therapeutics Inc Α4β7 integrin thioether peptide antagonists
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
WO2016040570A2 (en) 2014-09-12 2016-03-17 Children's Medical Center Corporation Dietary emulsion formulations and methods for using the same
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3168135A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11845808B2 (en) 2020-01-15 2023-12-19 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021316000A1 (en) * 2020-07-28 2023-02-16 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
US11939361B2 (en) 2020-11-20 2024-03-26 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of Interleukin-23 receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5850213B2 (ja) * 1977-06-20 1983-11-09 株式会社第一ラジオアイソト−プ研究所 カルチトニンの定量法
US4493795A (en) * 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US5639671A (en) * 1989-09-18 1997-06-17 Biostar, Inc. Methods for optimizing of an optical assay device
EP0506855A1 (de) 1989-12-15 1992-10-07 Chiron Corporation Cytokin-antikörper zur behandlung von sepsis
JP2955082B2 (ja) * 1991-10-11 1999-10-04 大阪瓦斯株式会社 ヒトカルシトニンのｎ末端部分を特異的に認識するモノクローナル抗体
DE4227454C1 (de) * 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
US5660826A (en) * 1995-06-06 1997-08-26 The Regents Of The University Of California Therapeutic sepsis treatment using antagonists to PTHrP

Also Published As

Publication number Publication date
WO1998033524A1 (en) 1998-08-06
EP0988054B1 (de) 2009-03-04
CA2279517A1 (en) 1998-08-06
CA2279517C (en) 2010-05-11
ATE424218T1 (de) 2009-03-15
EP0988054A4 (de) 2005-01-05
EP0988054A1 (de) 2000-03-29
AU739645B2 (en) 2001-10-18
US5993811A (en) 1999-11-30
AU6030998A (en) 1998-08-25
JP2001527529A (ja) 2001-12-25

Similar Documents

Publication Publication Date Title
DE69840625D1 (de) Verfahren und zusammensetzungen zur prävention undichen reaktion einschliesslich der sepsis
ATE253073T1 (de) Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase
SE9801526D0 (sv) New compounds
EP1849478A3 (de) Antagonisten des Entzündungsmediators
ATE115160T1 (de) Biologisch abbaubare polyphosphoester.
DE69728594D1 (de) Chromfreie Zusammensetzung zur Behandlung von Metalloberflächen
NO20004053D0 (no) Glukokortikoid-selektive antiinflammatoriske midler
IT1129080B (it) Composizione e cartina di prova per la determinazione colorimetrica dell acido ascorbico
KR950700323A (ko) 엔케팔리나제 및 안지오텐신 전환 효소의 억제제로서 유용한 아미노아세틸머캅토아세틸아미드 유도체(Aminoacetylmercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ACE)
PT705100E (pt) Guanidinas substituidas terapeuticas
EA200100732A1 (ru) Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию
DE69739026D1 (de) Nitril-Hydratase, ihre Derivate und Verfahren zur Herstellung von Verbindungen
DE69723863D1 (de) Chinoline und deren therapeutische verwendung
SE9602286D0 (sv) New compounds
ATE175998T1 (de) Rekombinierte alkalische phosphatase aus kälberdarm
DE69720996D1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer
MA23587A1 (fr) Traitement du besoin en nicotine et/ou du syndrome de manque lie au tabagisme
IT1068320B (it) Composizione fosfatante liquida e metodo di suo impiego
TR200000907T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.
SE0102808D0 (sv) New compounds
ATE191568T1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
EE05182B1 (et) Asendatud homopiperidlbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
MA23588A1 (fr) Traitement du besoin en nicotine et/ou du syndrome de manque lie au tabagisme
BR9808974A (pt) Composição compreendendo pectina metil esterase e dois substratos
DK227090D0 (da) Organisk guldkompleks til topisk anvendelse

Legal Events

Date Code Title Description
8364 No opposition during term of opposition